Viral infections in atopic dermatitis: Pathogenic aspects and clinical management

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 4, 2003, Pages 667-674

  Wollenberg, Andreas ^a   Wetzel, Stefanie ^a   Burgdorf, Walter H C ^a   Haas, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atopic dermatitis; Cowpox; Eczema herpeticum; Eczema molluscatum; Eczema vaccinatum; Smallpox

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ALPHA INTERFERON; ALPHA1 INTERFERON; ANTIINFECTIVE AGENT; CALCINEURIN INHIBITOR; CEFADROXIL; CORTICOSTEROID; FAMCICLOVIR; FOSCARNET; GAMMA INTERFERON; GLUCOCORTICOID; IDOXURIDINE; IMMUNOGLOBULIN; INTERFERON; METISAZONE; PENCICLOVIR; TRIFLURIDINE; VACCINIA VACCINE; VALACICLOVIR;

ATOPIC DERMATITIS; BIRTH DEFECT; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COWPOX; COWPOX VIRUS; CURETTAGE; DIAGNOSTIC TEST; DISEASE COURSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ECZEMA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HYPOKALEMIA; INFLAMMATION; INOCULATION; INTRAUTERINE INFECTION; MOLLUSCIPOXVIRUS; MOLLUSCUM CONTAGIOSUM; NEPHROTOXICITY; ORTHOPOXVIRUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SMALLPOX; SMALLPOX VIRUS; SPONTANEOUS ABORTION; VACCINATION; VIRUS INFECTION; VIRUS PARTICLE; VIRUS TRANSMISSION;

EID: 0141991154     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.07.001     Document Type: Article

References (66)

1. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000;55:205-13.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361:151-60.
3. Engler RJM, Kenner J, Leung DY. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol 2002;110:357-65.
4. Wollenberg A, Wagner M, Günther S, Towarowski A, Tuma E, Moderer M, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:1096-102.
5. Senkevich TG, Bugert JJ, Sisler JR, Koonin EV, Darai G, Moss B. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 1996;273:813-6.
6. Xiang Y, Moss B. Molluscum contagiosum virus interleukin-18 (1L-18) binding protein is secreted as a full-length form that binds cell surface glycosaminoglycans through the C-terminal tail and a furin-cleaved form with only the IL-18 binding domain. J Virol 2003;77:2623-30.
7. Heng MC, Steuer ME, Levy A, McMahon S, Richman M, Allen SG, et al. Lack of host cellular immune response in eruptive molluscum contagiosum. Am J Dermatopathol 1989;11:248-54.
8. Solomon L, Telner P. Eruptive molluscum contagiosum in atopic dermatitis. CMAJ 1966;95:978-9.
9. Forghani B, Oshiro LS, Chan CS, Hurst JW, Dennis J, Darai G, et al. Direct detection of Molluscum contagiosum virus in clinical specimens by in situ hybridization using biotinylated probe. Mol Cell Probes 1992;6:67-77.
10. Syed TA, Goswami J, Ahmadpour OA, Ahmad SA. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998;25:309-13.
11. Wienecke R, Wolff H, Schaller M, Meyer H, Plewig G. Cowpox virus infection in an 11-year-old-girl. J Am Acad Dermatol 2000;42:892-4.
12. Eis-Hubinger AM, Gerritzen A, Schneweis KE, Pfeiff B, Pullmann H, Mayr A, et al. Fatal cowpox-like virus infection transmitted by cat. Lancet 1990;336:880.
13. Blackford S, Roberts DL, Thomas PD. Cowpox infection causing a generalized eruption in a patient with atopic dermatitis. Br J Dermatol 1993;129:628-9.
14. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. The pathogenesis, immunology and pathology of smallpox and vaccinia. Geneva: World Health Organization; 1988. p. 122-67.
15. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998;79:1159-67.
16. Copeman PWM, Wallace HJ. Eczema vaccinatum. BMJ 1964;2:906-8.
17. Lane JM, Millar JD. Risk of smallpox vaccination complications in the United States. Am J Epidemiol 1971;93:238-40.
18. Highet AS, Kurst J. Viral infections. In: Champion RH, Burton JL, Edling FJG, editors. Textbook of dermatology. 5th ed. London: Blackwell; 1992. p. 872-3.
19. Haim M, Gdalevich M, Mimouni D, Ashkenazi I, Shemer J. Adverse reactions to smallpox vaccine: the Israel Defense Force experience, 1991 to 1996. A comparison with previous surveys. Mil Med 2000;165:287-9.
20. Drazen JM. Smallpox and bioterrorism. N Engl J Med 2002;346:1262-3.
21. Gruchalla RS, Jones J. Combating high-priority biological agents: what to do with drug-allergic patients and those for whom vaccination is contraindicated? J Allergy Clin Immunol 2003;112:675-82.
22. Kempe CH. Studies on smallpox and complications of smallpox vaccination. Pediatrics 1968;26:176-89.
23. Bicknell WJ. The case for voluntary smallpox vaccination. N Engl J Med 2002;346:1323-5.
24. Hackett CJ. Innate immune activation as a broad spectrum biodefense strategy - prospects and research challenges. J Allergy Clin Immunol 2003;112:686-94
25. Kaposi M. Pathologie und Therapie der Hautkrankheiten. Vol. 3. Wien: Urban und Schwarzenberg; 1887.
26. Higgins CR, Schofield JK, Tatnall FM, Leigh IM. Natural history, management and complications of herpes labialis. J Med Virol 1993;Suppl 1:22-6.
27. Martins-Castro R, Proenca N, de Salles-Gomes LF. On the association of some dermatoses with South American pemphigus foliaceus. Int J Dermatol 1974;13:271-5.
28. Masessa JM, Grossman ME, Knobler EH, Bank DE. Kaposi's varicelliform eruption in cutaneous T cell lymphoma. J Am Acad Dermatol 1989;21:133-5.
29. Brion N, Guillaume JC, Dubertret L, Touraine R. Disseminated cutaneous herpes of the adult and Sezary syndrome. Ann Dermatol Venereol 1981;108:517-21.
30. Verbov J. Fixed drug eruption due to phenazone in a hypnotic. Br J Dermatol 1972;86:438.
31. Schirren H, Schirren C, Schlüpen E, Volkenandt M, Kind P. Exacerbation of Hailey-Hailey disease by infection with herpes simplex virus. Detection with polymerase chain reaction. Hautarzt 1995;46:494-7.
32. Nishimura M, Maekawa M, Hino Y, Mihara K, Kohda H. Kaposi's varicelliform eruption. Development in a patient with a healing second-degree burn. Arch Dermatol 1984;120:799-800.
33. Sanderson IR, Brueton LA, Savage MO, Harper JI. Eczema herpeticum: a potentially fatal disease. BMJ 1987;294:693-4.
34. Wheeler CE Jr, Abele DC. Eczema herpeticum, primary and recurrent. Arch Dermatol 1966;93:162-73.
35. Bork K, Brauninger W. Increasing incidence of eczema herpeticum: analysis of seventy-five cases. J Am Acad Dermatol 1988;19:1024-9.
36. Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum - a retrospective analysis of 100 cases. J Am Acad Dermatol 2003;49:198-205.
37. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002;110:e2.
38. Yoon M, Spear PG. Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol 2002;76:7203-8.
39. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I Interferon. Nat Med 1999;5:919-23.
40. Uchida Y, Kurasawa K, Nakajima H, Nakagawa N, Tanabe E, Sueishi M, et al. Increase of dendritic cells of type 2 (DC2) by altered response to IL-4 in atopic patients. J Allergy Clin Immunol 2001;108:1005-11.
41. Gallo RL, Murakami M, Ohtake T, Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002;110:823-31.
42. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60.
43. Ganz T. Defensins and host defense. Science 1999;286:420-1.
44. Virella-Lowell I, Poirier A, Chesnut KA, Brantly M, Flotte TR. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 2000;7:1783-9.
45. Jones JF, Howell MD, Kisich KO, Streib JE, Gallo RL, Leung DYM. Deficiency of LL-37 in atopic skin may contribute to eczema vaccinatum (EV). J Allergy Clin Immunol 2003;111:908.
46. McGrath N, Anderson N, Croxson M, Powell K. Herpes simple encephalitis treated with acyclovir: diagnosis and long term outcome. J Neurol Neurosurg Psychiatry 1997;63:321-6.
47. Niimura M, Nishikawa T, Martin A, Booth A, Brocklehurst P, Kinghorn G, et al. Treatment of eczema herpeticum with oral acyclovir. Am J Med 1988;85:49-52.
48. Modiano P, Salloum E, Gillet-Terver MN, Barbaud A, Georges JC, Thouvenot D, et al. Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrome. Br J Dermatol 1995;133:475-8.
49. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996;52:754-72.
50. Wollenberg A, Degitz K. Eczema herpeticatum in graviditate. Dtsch Med Wochenschr 1995;120:1395-8.
51. Rappersberger K. Infektionen mit Herpes-simplex und Varizella-Zoster-Viren in der Schwangerschaft. Klinische Manifestationen bei Mutter, Fötus und Neugeborenen- therapeutische Optionen. Hautarzt 1999;50:706-14.
52. Lazarus HM, Belanger R, Candoni A, Aoun M, Jurewicz R, Marks L. Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study Group. Antimicrob Agents Chemother 1999;43:1192-7.
53. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs 1995;50:396-415.
54. Safrin S, Crumpacker C, Chatis P, Davis R, Hafner R, Rush J, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991;325:551-5.
55. Wollenberg A, Baldauf C, Ruëff F, Przybilla B. Allergische Kontaktdermatitis und Arzneiexanthem auf Aciclovir - Kreuzreaktion auf Ganciclovir. Allergo J 2000;9:96-9.
56. Lin L, Chen XS, Cui G, Wang JB, Guo ZP, Lu NZ, et al. Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. J Dermatolog Treat 2002;13:67-72.
57. Noisakran SJ, Carr DJ. Therapeutic efficacy of DNA encoding IFN-alpha1 against corneal HSV-1 infection. Curr Eye Res 2000;20:405-12.
58. Kessler HA, Hurwitz S, Farthing C, Benson CA, Feinberg J, Kuritzkes DR, et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 1996;12:147-52.
59. Tabery HM. Healing of recurrent herpes simplex corneal epithelial lesions treated with topical acyclovir. A non-contact photomicrographic in vivo study in the human cornea. Acta Ophthalmol Scand 2001;79:256-61.
60. Wilhelmus K. The treatment of herpes simplex virus epithelial keratitis. Trans Am Ophthalmol Soc 2000;98:505-32.
61. Panda A, Das GK, Khokhar S, Rao V, Nevin T, Korvick JA. Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis. Can J Ophthalmol 1995;30:256-8.
62. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994;343:1460-3.
63. Harrison CJ, Miller RL, Bernstein DI. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001;19:1820-6.
64. Mikloska Z, Cunningham AL. Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission. J Virol 2001;75:11821-6.
65. Schultz-Larsen F, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:1-24.
66. Charatan F. US doctors investigate more than 50 possible cases of monkeypox. BMJ 2003;326:1350.